Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,682 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
Shinno Y, Yoshida A, Masuda K, Matsumoto Y, Okuma Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Yatabe Y, Ohe Y. Shinno Y, et al. Among authors: masuda k. Clin Lung Cancer. 2022 Jul;23(5):386-392. doi: 10.1016/j.cllc.2022.03.005. Epub 2022 Apr 29. Clin Lung Cancer. 2022. PMID: 35618627
Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.
Shirasawa M, Yoshida T, Takayanagi D, Shiraishi K, Yagishita S, Sekine K, Kanda S, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Hamada A, Kohno T, Yamamoto N, Watanabe SI, Ohe Y, Motoi N. Shirasawa M, et al. Among authors: masuda k. Clin Lung Cancer. 2021 Jul;22(4):282-291.e6. doi: 10.1016/j.cllc.2021.02.003. Epub 2021 Feb 8. Clin Lung Cancer. 2021. PMID: 33722498
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression.
Takumida H, Horinouchi H, Masuda K, Shinno Y, Okuma Y, Yoshida T, Goto Y, Yamamoto N, Ohe Y. Takumida H, et al. Among authors: masuda k. Cancer Immunol Immunother. 2022 Mar;71(3):737-746. doi: 10.1007/s00262-021-03029-9. Epub 2021 Aug 14. Cancer Immunol Immunother. 2022. PMID: 34389874 Free PMC article.
Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
Shirasawa M, Yoshida T, Shimoda Y, Takayanagi D, Shiraishi K, Kubo T, Mitani S, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Ichikawa H, Kohno T, Yamamoto N, Matsumoto S, Goto K, Watanabe SI, Ohe Y, Motoi N. Shirasawa M, et al. Among authors: masuda k. J Thorac Oncol. 2021 Dec;16(12):2078-2090. doi: 10.1016/j.jtho.2021.07.027. Epub 2021 Aug 20. J Thorac Oncol. 2021. PMID: 34419685 Free article.
2,682 results